STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: In several imatinib-resistant CML cell lines such as K562R, LAMA84R, and KCL22R, simvastatin, one of the most pharmacologically potent inhibitors of HMG-CoA reductase, was found to have a synergistic killing effect by induction of apoptosis and cell cycle arrest by inhibiting tyrosine phosphorylation and activating STAT5 and STAT3 [41].